IL-6 as the key inflammatory mediator controlling GVHD

IL-6作为控制GVHD的关键炎症介质

• 批准号: nhmrc : 1070563
• 负责人: A/Pr Kelli Macdonald
• 金额: $ 39.48万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/il-6-key-controlling-gvhd/455434
• 关键词: IL; key; inflammatory; mediator; controlling

Allogeneic haematopoietic stem cell transplantation (SCT) is a curative treatment for blood cancers. Graft-versus-host disease (GVHD) is a major limitation which occurs when the newly transplanted immune system mounts a rejection response against the recipient and is responsible for the death of up to 40% of transplant recipients. These studies will optimize a new approach to prevent GVHD focusing on a protein called interleukin-6. Ultimately, it is anticipated such approaches will improve the overall survival of patients with blood cancers.

同种异体造血干细胞移植（SCT）是一种治疗血癌的方法。移植物抗宿主病 (GVHD) 是一种主要限制，当新移植的免疫系统对受者产生排斥反应时就会发生这种疾病，并导致高达 40% 的移植受者死亡。这些研究将优化一种预防 GVHD 的新方法，重点关注一种称为白细胞介素 6 的蛋白质。最终，预计此类方法将提高血癌患者的总体生存率。